2025
CARG-2020 targets IL-12, IL-17, and PD-L1 pathways to effectively treat melanoma and breast cancer
Ahmadi E, Chiari C, Madina B, Yarovinsky T, Krady M, Chen J, Almassian B, Nakaar V, Wang K. CARG-2020 targets IL-12, IL-17, and PD-L1 pathways to effectively treat melanoma and breast cancer. Scientific Reports 2025, 15: 29649. PMID: 40804279, PMCID: PMC12350727, DOI: 10.1038/s41598-025-14750-1.Peer-Reviewed Original ResearchConceptsColorectal cancerPD-L1Oncolytic virusesBroad-spectrum efficacySystemic deliveryIL-12Accumulation of CD8+ T lymphocytesBreast cancerGenetically engineered oncolytic virusesMouse modelCD8+ T lymphocytesMouse model of melanomaTriple-negative breast cancerPD-L1 pathwayPoor tumor regressionPD-L1 expressionIL-17RA signalingModel of melanomaCytokines IL-12Colorectal cancer growthCancer immunotherapyTumor regressionT cellsSolid tumorsMultiple human cancers
2006
Topiramate for the treatment of epilepsy and other nervous system disorders
van Passel L, Arif H, Hirsch LJ. Topiramate for the treatment of epilepsy and other nervous system disorders. Expert Review Of Neurotherapeutics 2006, 6: 19-31. PMID: 16466308, DOI: 10.1586/14737175.6.1.19.Peer-Reviewed Original ResearchConceptsPossible neuroprotective agentsTroublesome adverse effectsOral hypoglycemic agentsCognitive side effectsTreatment of epilepsyNervous system disordersNeuropathic painMigraine prophylaxisNeuroprotective agentsHypoglycemic agentsSystem disordersSide effectsBroad-spectrum efficacyBipolar disorderLow dosesPsychiatric conditionsTopiramateSubstance dependenceAdverse effectsEpilepsyDisordersEfficacySpectrum efficacyMonotherapyProphylaxis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply